Richard Alan Furie, MD

Call Email

Professor, Institute of Molecular Medicine, Feinstein Institutes for Medical Research
Chief, Division of Rheumatology, Northwell Health
Marilyn and Barry Rubenstein Chair in Rheumatology and Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

About the investigator

Richard Alan Furie, MD, chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, Northwell Heath’s clinical research program, in musculoskeletal disease. He also directs the SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for systemic lupus (SLE). Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance and Lupus Therapeutics. For 20 years, he served on many committees of the American College of Rheumatology and was named a master of the college in 2018. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with his colleagues and trainees.

Research focus

Dr. Furie’s research focus has been in SLE and related diseases, such as the antiphospholipid syndrome. Specifically, he has played an instrumental role in drug development and clinical trial design in SLE and lupus nephritis. Known as The Program in Novel Therapeutics, the division’s research program has established itself as an international leader in clinical trials.

Education

The Hospital for Special Surgery
Degree: Fellowship
Field of study: Rheumatology
1984

The New York Hospital
Degree: Residency
Field of study: Internal medicine
1982

Cornell University Medical College
Degree: MD
1979

Cornell University College of Arts and Sciences
Degree: AB
1974

Honors & awards

2020 Department of Medicine Research Award
2018 Master, American College of Rheumatology
2014 Arthritis Foundation Walk Honoree
2010 Long Island’s Top Doctors
2005 America's Top Physicians
2002, 2010 New York Magazine Best Doctors
1999 Top Doctors: NY Metro Area
1997 Top Doctors: NY Metro Area
1982-1983 Fellow of the Arthritis Foundation
1981 Assistant Chief Resident, New York Hospital
1974 A.B. Magna cum laude

Publications

Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021 Feb;8(1):e000464. doi: 10.1136/lupus-2020-000464. PMID: 33597205.
Ptacek J, Hawtin RE, Sun D, Louie B, Evensen E, Mittleman BB, Cesano A, Cavet G, Bingham CO 3rd, Cofield SS, Curtis JR, Danila MI, Raman C, Furie RA, Genovese MC, Robinson WH, Levesque MC, Moreland LW, Nigrovic PA, Shadick NA, O'Dell JR, Thiele GM, Clair EWS, Striebich CC, Hale MB, Khalili H, Batliwalla F, Aranow C, Mackay M, Diamond B, Nolan GP, Gregersen PK, Bridges SL Jr. Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. PLoS One. 2021 Jan 14;16(1):e0244187. doi: 10.1371/journal.pone.0244187. PMID: 33444321.
Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Rheumatol Ther. 2020 Dec;7(4):893-908. doi: 10.1007/s40744-020-00236-1. Epub 2020 Sep 29. PMID: 32996096; PMCID: PMC7695765.
Chatham WW, Furie RA, Saxena A, Brohawn P, Schwetje E, Abreu G, Tummala R. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase 2 open-label extension study. Arthritis Rheumatol. 2020 Nov 22. doi: 10.1002/art.41598. Epub ahead of print. PMID: 33225631.
Furie RA, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.

Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 Apr;7(1):e000377. doi: 10.1136/lupus-2019-000377.
Morand EF, Furie RA, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020 Jan 16; 382(3): 211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
Askanase AD, Zhao E, Zhu J, Connolly-Strong E, Furie RA. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial. Lupus Science & Medicine 2020;7:e000383. doi:10.1136/lupus-2020-000383.

View more at PubMed

(516) 562-FIMR

The Feinstein Institutes—the research institutes of Northwell Health, New York’s largest health care provider—is home to 50 research labs, 3,000 clinical research studies and 5,000 people raising the standard of medical innovation. We make breakthroughs in molecular medicine, genetics, cancer, brain research, mental health, autoimmunity and bioelectronic medicine.

Quick links

Connect

About

Employees

We are Northwell Health—and together, we're raising the standard of health care.